NASH-246 remains a placeholder, but the fragment you provided underscores a critical truth in clinical research: . When researchers write “just ask,” they combat the inertia of “assumed continuation.” As NASH/MASH therapies approach market, dozens of phase III trials will need this patient-first mindset.
), which is a key therapeutic candidate in the Nonalcoholic Steatohepatitis (NASH) pipeline. NASH-246 from there-once again just ask......
The phrase ensures that site coordinators do not assume continuation. Each transition requires renewed patient agency. NASH-246 remains a placeholder, but the fragment you